SCHEMBL12419260

SCHEMBL12419260

OB(O)c1ccc2cc(Oc3ncccn3)ccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.58
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
APAF1 O14727 1/20 0.44
MAPT P10636 3/20 0.42
NPC1 O15118 1/20 0.42
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 3/20 0.40
ENPP2 Q13822 2/20 0.40
TLR4 O00206 1/20 0.38
TLR2 O60603 1/20 0.38
HSD17B10 Q99714 2/20 0.38
GAA P10253 3/20 0.36
HPGD P15428 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12419258 0.83 CA1 (0.51) RAB9ACA1CA2KDM4ETLR4
SCHEMBL5687378 0.77 RAB9A (0.64) RAB9AMEN1KMT2AAPAF1MAPT
SCHEMBL8437226 0.77 CA1 (0.71) CA1CA2MEN1KMT2AENPP2
SCHEMBL12419259 0.75 KDM4E (0.47) RAB9ACA1CA2MEN1KMT2A
SCHEMBL9210 0.74 ENPP2 (0.65) RAB9ACA1CA2MAPTNPC1
SCHEMBL29410294 0.74 ENPP2 (0.65) RAB9ACA1CA2MAPTNPC1
SCHEMBL205203 0.73 CA2 (0.80) CA1CA2KDM4EALDH1A1ENPP2
SCHEMBL31354846 0.73 CA2 (0.80) CA1CA2KDM4EALDH1A1ENPP2
SCHEMBL25231264 0.72 ENPP2 (0.52) CA1CA2MEN1KMT2AMAPT
SCHEMBL31050997 0.72 ENPP2 (0.52) CA1CA2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 RAB9A 1820/4885CA1 822/4885CA2 1487/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 RAB9A 1820/4885CA1 822/4885CA2 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.